drugs glp-1 Agonists: A Comprehensive Overview GLP-1 Drugs Cut Risk of

In June 2025, Amgen announced positive Phase 2 trial results for MariTide showing up to ~20% weight loss in obese patients and ~17% in type 2 diabetes patients, presented at the ADA 85th scientific sessions

Based on recent studies, SGLT2 inhibitors (SGLTis) are generally considered superior to GLP-1 receptor agonists (GLP-1s) for slowing the progression of chronic kidney disease

In previous large-scale clinical trials of GLP-1RAs, 15.2% ( n = 618) of AMPLITUDE-O and 6.1% ( n = 575) of Harmony Outcomes patients used SGLT2is at baseline [18, 20] (Table 1)

CNS Drugs

The study randomized 445 participants in a 1:1:1 ratio to receive either retatrutide 9 mg or 12 mg, or placebo

Subcutaneous injections dominate this segment with a 64% market share, offering robust efficacy and established preference among healthcare providers